从中国的结核病控制中可以吸取教训.

Methodology and scope of peer-reviewed evaluations of TB programmes in high-incidence settings: a scoping review.

The international journal of tuberculosis and lung disease : the official journal of the International Union against Tuberculosis and Lung Disease·2026

Early interventions reduce multimorbidity and TB disability in Kenya, Uganda, Zambia, and Zimbabwe.

IJTLD open·2026

Operational research to End TB: 2nd edition of the Union's Guide to operational research.

The international journal of tuberculosis and lung disease : the official journal of the International Union against Tuberculosis and Lung Disease·2025

Kartagener Syndrome: A First Report of Two Cases from Benin, West Africa.

West African journal of medicine·2025

Evaluating disability, comorbidities and risk factors after TB treatment: an 18-24 month follow-up.

IJTLD open·2025

TB disability and multimorbidity at the onset of treatment in Kenya, Uganda, Zambia and Zimbabwe.

IJTLD open·2025

1-month versus 12-month dual antithrombotic therapy after percutaneous coronary intervention in patients with atrial fibrillation (OPTIMA-AF): a multicentre, open-label, hybrid non-inferiority and superiority, randomised, controlled trial.

Lancet (London, England)·2026

Multidomain lifestyle intervention for the prevention of cognitive decline in at-risk older adults in Latin America (LatAm-FINGERS): a single-blind, multicentre, randomised controlled trial.

Lancet (London, England)·2026

Advancing the relevance of clinical trials for older patients.

Lancet (London, England)·2026

Temocillin versus carbapenems for bacteraemia due to third-generation cephalosporin-resistant Enterobacterales in Spain (ASTARTÉ): a multicentre, phase 3, open-label, non-inferiority, randomised clinical trial.

Lancet (London, England)·2026

Fixed-duration pirtobrutinib plus venetoclax-rituximab versus venetoclax-rituximab for patients with previously treated chronic lymphocytic leukaemia or small lymphocytic lymphoma (BRUIN CLL-322): an open-label, multicentre, randomised, controlled, phase 3 trial.

Lancet (London, England)·2026

Children in all policies: lessons from a global collaboration to promote the health and wellbeing of children and future generations.

Lancet (London, England)·2026

An herbal formula alleviates hyperuricemia: Evidence from network pharmacology and in vivo experiments.

Combinatorial chemistry & high throughput screening·2026

Behavioral and Molecular Effects of Kamikihito and Mesenchymal Stem Cells in a Two-hit Model of Treatment-resistant Depression.

Current neuropharmacology·2026

Effect of Educational and Behavioral Interventions on Medication-Overuse Headache: A Systematic Review and Meta-Analysis.

Pain research & management·2026

Diffusion tensor imaging in chronic tension-type headache.

Frontiers in pain research (Lausanne, Switzerland)·2026

Multidimensional therapeutic advantages of Smilax glabra (Tufuling)-containing formulae in gout: an integrated Systematic Review and network pharmacology-based prediction.

Frontiers in endocrinology·2026

Evaluating combined acupuncture and antiresorptive therapy in Chinese women with postmenopausal osteoporosis: a systematic review and network meta-analysis.

Frontiers in endocrinology·2026

相关实验视频

从中国的结核病控制中可以吸取教训.

相关概念视频

Methodology and scope of peer-reviewed evaluations of TB programmes in high-incidence settings: a scoping review.

Early interventions reduce multimorbidity and TB disability in Kenya, Uganda, Zambia, and Zimbabwe.

Operational research to End TB: 2<sup>nd</sup> edition of the Union's Guide to operational research.

Kartagener Syndrome: A First Report of Two Cases from Benin, West Africa.

Evaluating disability, comorbidities and risk factors after TB treatment: an 18-24 month follow-up.

TB disability and multimorbidity at the onset of treatment in Kenya, Uganda, Zambia and Zimbabwe.

1-month versus 12-month dual antithrombotic therapy after percutaneous coronary intervention in patients with atrial fibrillation (OPTIMA-AF): a multicentre, open-label, hybrid non-inferiority and superiority, randomised, controlled trial.

Multidomain lifestyle intervention for the prevention of cognitive decline in at-risk older adults in Latin America (LatAm-FINGERS): a single-blind, multicentre, randomised controlled trial.

Advancing the relevance of clinical trials for older patients.

Temocillin versus carbapenems for bacteraemia due to third-generation cephalosporin-resistant Enterobacterales in Spain (ASTARTÉ): a multicentre, phase 3, open-label, non-inferiority, randomised clinical trial.

Fixed-duration pirtobrutinib plus venetoclax-rituximab versus venetoclax-rituximab for patients with previously treated chronic lymphocytic leukaemia or small lymphocytic lymphoma (BRUIN CLL-322): an open-label, multicentre, randomised, controlled, phase 3 trial.

Children in all policies: lessons from a global collaboration to promote the health and wellbeing of children and future generations.

An herbal formula alleviates hyperuricemia: Evidence from network pharmacology and in vivo experiments.

Behavioral and Molecular Effects of Kamikihito and Mesenchymal Stem Cells in a Two-hit Model of Treatment-resistant Depression.

Effect of Educational and Behavioral Interventions on Medication-Overuse Headache: A Systematic Review and Meta-Analysis.

Diffusion tensor imaging in chronic tension-type headache.

Multidimensional therapeutic advantages of <i>Smilax glabra</i> (<i>Tufuling</i>)-containing formulae in gout: an integrated Systematic Review and network pharmacology-based prediction.

Evaluating combined acupuncture and antiresorptive therapy in Chinese women with postmenopausal osteoporosis: a systematic review and network meta-analysis.

相关实验视频

从中国的结核病控制中可以吸取教训.

相关概念视频

相关文章